• 简

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    Learn Why The Bull Case For ICU Medical (ICUI) Could Change Following Earnings Beat

    Simply Wall St·11/07/2026 06:28:55
    语音播报
    • ICU Medical reported Q3 2026 sales of US$560.44 million, net income of US$26.85 million, and basic earnings per share of US$1.07 from continuing operations, compared with a loss a year earlier.
    • The nine month figures showed sales of US$1.64b alongside a rise in earnings per share from continuing operations, pointing to improved profitability despite slightly lower revenue than the prior period.
    • We will look at how ICU Medical's investment narrative is shaped by stronger earnings and reaffirmed full year profitability guidance.
    Capitalize on ICU Medical's earnings momentum by scanning a curated group of financially resilient peers using the list of solid balance sheet and fundamentals (24 results).

    ICU Medical Investment Narrative Recap

    For an investor to stay with ICU Medical, belief needs to center on a cleaner, higher margin infusion and consumables platform that can fund ongoing product upgrades while digesting past acquisitions. The latest quarter supports that narrative, with higher earnings and reaffirmed full year profitability targets, even as nine month sales sit slightly below the prior period.

    The near term swing factor is still execution on margin expansion and manufacturing integration, including tariff headwinds and Vital Care’s weaker profile. Recent results suggest progress but do not remove the risk that regulatory issues, plant transitions or logistics disruptions could still pressure earnings or slow future product launches.

    The most relevant update tied to this earnings print is management’s reaffirmation of full year adjusted EPS and EBITDA guidance. Q3 adjusted EPS of US$2.44 and revenue around US$560 million both exceeded market expectations. Taken together, these figures indicate that the business is currently tracking at, or slightly ahead of, its own operating plan.

    For catalysts, the reaffirmed outlook keeps attention on execution in Infusion Systems and Consumables, along with the planned margin improvements into 2027. On the risk side, the same update also keeps tariffs, Vital Care softness and ongoing integration costs in focus, since any stumble in these areas could quickly change the tone of future guidance.

    ICU Medical's current analyst narrative points to revenues of US$2.5b and earnings of US$173.2 million by 2029, built on an assumed 4.5% yearly revenue growth rate and an increase in earnings from US$30.1 million today. This implies earnings would need to rise by about 6x from current levels.

    Uncover why ICU Medical's fair value indicates an 11% potential upside to its current price that could narrow quickly.

    NasdaqGS:ICUI 1-Year Stock Price Chart
    NasdaqGS:ICUI 1-Year Stock Price Chart

    Form Your Own Verdict

    Don't just follow the ticker. Dig into the data and build a conviction that's truly your own.

    Looking for more ICU Medical investment ideas?

    If the ICU Medical story has sharpened your thinking about quality and risk, use that same lens to scan the wider market with the Simply Wall St Screener. It helps you quickly zero in on stocks that fit the balance sheet strength, value, or income profile you care about most.

    • For investors who care most about resilient finances, start with a curated list of solid balance sheet and fundamentals (24 results) that can handle tougher conditions without stretching their resources.
    • If value is your priority, hunt for quality businesses that the market may be pricing cautiously by reviewing the 39 high quality undervalued stocks that pair fundamentals with more modest expectations.
    • Income focused readers can round out their watchlist by checking out a hand picked set of yield candidates in the 8 dividend fortresses that combine higher payouts with a focus on durability.